378 related articles for article (PubMed ID: 29134684)
1. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.
Ghashghaei M; Niazi TM; Aguilar-Mahecha A; Klein KO; Greenwood CMT; Basik M; Muanza TM
Sci Rep; 2019 Jun; 9(1):8838. PubMed ID: 31221986
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
Sekhar KR; Wang J; Freeman ML; Kirschner AN
PLoS One; 2019; 14(4):e0214670. PubMed ID: 30933998
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Basu HS; Wilganowski N; Robertson S; Reuben JM; Cohen EN; Zurita A; Ramachandran S; Xiao LC; Titus M; Wilding G
Prostate; 2021 Sep; 81(12):799-811. PubMed ID: 34170017
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An
Triggiani L; Colosini A; Buglione M; Pasinetti N; Orizio F; Bardoscia L; Borghetti P; Maddalo M; Spiazzi L; Magrini SM; Bresciani R
Anticancer Res; 2018 Jun; 38(6):3487-3492. PubMed ID: 29848701
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.
Gecgel KK; Muduroglu M; Erdogan S
J BUON; 2017; 22(6):1570-1576. PubMed ID: 29332354
[TBL] [Abstract][Full Text] [Related]
9. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
10. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
12. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Kim J; Park S; Kim S; Ryu S; Hwang H; Cho S; Han Y; Kim J; Park Y; Lee EK; Lee M
Prostate; 2024 Jun; 84(9):814-822. PubMed ID: 38558458
[TBL] [Abstract][Full Text] [Related]
14. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
15. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
16. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.
Malaquin N; Vancayseele A; Gilbert S; Antenor-Habazac L; Olivier MA; Ait Ali Brahem Z; Saad F; Delouya G; Rodier F
Cells; 2020 Jul; 9(7):. PubMed ID: 32630281
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines.
Fragni M; Galli D; Nardini M; Rossini E; Vezzoli S; Zametta M; Longhena F; Bellucci A; Roca E; Memo M; Berruti A; Sigala S
Naunyn Schmiedebergs Arch Pharmacol; 2019 Jun; 392(6):729-742. PubMed ID: 30770950
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
[TBL] [Abstract][Full Text] [Related]
19. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Enzalutamide Prior to Prostatectomy.
Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M; Novotny W; Wu K; Kantoff PW; Marck BT; Plymate S; Balk SP; Nelson PS; Matsumoto AM; Lis RT; Kibel A; Haas GP; Krivoshik A; Hannah A; Taplin ME
Clin Cancer Res; 2017 May; 23(9):2169-2176. PubMed ID: 28151719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
